These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 25216787)

  • 1. Nitric oxide in the normal kidney and in patients with diabetic nephropathy.
    Tessari P
    J Nephrol; 2015 Jun; 28(3):257-68. PubMed ID: 25216787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Normalization of the ratio of nitric oxide and peroxynitrite by promoting eNOS dimer activity is a new direction for diabetic nephropathy treatment].
    Kan QM; Hu YH; He ZG
    Sheng Li Xue Bao; 2022 Feb; 74(1):93-109. PubMed ID: 35199130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy.
    Satoh M; Fujimoto S; Haruna Y; Arakawa S; Horike H; Komai N; Sasaki T; Tsujioka K; Makino H; Kashihara N
    Am J Physiol Renal Physiol; 2005 Jun; 288(6):F1144-52. PubMed ID: 15687247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy.
    Satoh M; Fujimoto S; Arakawa S; Yada T; Namikoshi T; Haruna Y; Horike H; Sasaki T; Kashihara N
    Nephrol Dial Transplant; 2008 Dec; 23(12):3806-13. PubMed ID: 18596126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.
    Onozato ML; Tojo A; Goto A; Fujita T; Wilcox CS
    Kidney Int; 2002 Jan; 61(1):186-94. PubMed ID: 11786100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are reactive oxygen species still the basis for diabetic complications?
    Di Marco E; Jha JC; Sharma A; Wilkinson-Berka JL; Jandeleit-Dahm KA; de Haan JB
    Clin Sci (Lond); 2015 Jul; 129(2):199-216. PubMed ID: 25927680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low nitric oxide bioavailability upregulates renal heparin binding EGF-like growth factor expression.
    Miyazawa T; Zeng F; Wang S; Fan X; Cheng H; Yang H; Bian A; Fogo AB; Harris RC
    Kidney Int; 2013 Dec; 84(6):1176-88. PubMed ID: 23760291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing kidney DDAH-1 expression by adenovirus delivery reduces ADMA and ameliorates diabetic nephropathy.
    Wetzel MD; Gao T; Stanley K; Cooper TK; Morris SM; Awad AS
    Am J Physiol Renal Physiol; 2020 Feb; 318(2):F509-F517. PubMed ID: 31904280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetylcysteine protects against diabetic nephropathy through control of oxidative and nitrosative stress by recovery of nitric oxide in rats.
    Nogueira GB; Punaro GR; Oliveira CS; Maciel FR; Fernandes TO; Lima DY; Rodrigues AM; Mouro MG; Araujo SRR; Higa EMS
    Nitric Oxide; 2018 Aug; 78():22-31. PubMed ID: 29778909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin enhanced nitric oxide release and reduced blood pressure, nitroxidative stress and rantes levels in hypertensive rats with diabetes.
    Mason RP; Corbalan JJ; Jacob RF; Dawoud H; Malinski T
    J Physiol Pharmacol; 2015 Feb; 66(1):65-72. PubMed ID: 25716966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxynitrite plays a key role in glomerular lesions in diabetic rats.
    Xiao H; Li Y; Qi J; Wang H; Liu K
    J Nephrol; 2009; 22(6):800-8. PubMed ID: 19967660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions.
    Balakumar P; Arora MK; Ganti SS; Reddy J; Singh M
    Pharmacol Res; 2009 Jul; 60(1):24-32. PubMed ID: 19427582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of free radicals and reactive nitrogen species in the late complications of diabetes mellitus in rats].
    Stadler K; Jenei V; von Bölcsházy G; Somogyi A; Jakus J
    Orv Hetil; 2004 May; 145(21):1135-40. PubMed ID: 15206194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies.
    Pacher P; Obrosova IG; Mabley JG; Szabó C
    Curr Med Chem; 2005; 12(3):267-75. PubMed ID: 15723618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apelin‑13 alleviates diabetic nephropathy by enhancing nitric oxide production and suppressing kidney tissue fibrosis.
    Gao Z; Zhong X; Tan YX; Liu D
    Int J Mol Med; 2021 Sep; 48(3):. PubMed ID: 34278446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrogen Sulfide: Recent Progression and Perspectives for the Treatment of Diabetic Nephropathy.
    Sun HJ; Wu ZY; Cao L; Zhu MY; Liu TT; Guo L; Lin Y; Nie XW; Bian JS
    Molecules; 2019 Aug; 24(15):. PubMed ID: 31390847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy?
    Balakumar P; Chakkarwar VA; Krishan P; Singh M
    Biomed Pharmacother; 2009 Mar; 63(3):171-9. PubMed ID: 18823739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy.
    Elmarakby AA; Sullivan JC
    Cardiovasc Ther; 2012 Feb; 30(1):49-59. PubMed ID: 20718759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production.
    Prabhakar S; Starnes J; Shi S; Lonis B; Tran R
    J Am Soc Nephrol; 2007 Nov; 18(11):2945-52. PubMed ID: 17928507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes.
    Bitar MS; Wahid S; Mustafa S; Al-Saleh E; Dhaunsi GS; Al-Mulla F
    Eur J Pharmacol; 2005 Mar; 511(1):53-64. PubMed ID: 15777779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.